SELENOP and metabolic dysfunction-associated steatotic liver disease: In detail, it was seen how the levels of these mediators varied in NAFLD with SeP (Chen et al., 2021) and aHSGF (Pan et al., 2020) appearing to be increased and PYY and GLP-1 levels reduced (Tarantino and Balsano, 2020).